BACKGROUND: Bacteremia is often one factor used in deciding the need for prolonged intravenous antimicrobial therapy in osteoarticular infections (OAIs). We examined treatment practices and outcomes of Staphylococcus aureus bacteremic osteoarticular infections (BOAIs) evaluated at Texas Children's Hospital. METHODS: Cases of acute hematogenous OAI in children with positive blood cultures for S. aureus at Texas Children's Hospital between 2011 and 2014 were reviewed. Orthopedic complications included chronic osteomyelitis, growth arrest, pathologic fracture, avascular necrosis and chronic dislocation. Acute kidney injury was defined as a doubling of the baseline creatinine. RESULTS: One hundred and ninety-two cases of S. aureus OAI were identified with 102 cases of BOAI included [35 methicillin-resistant S. aureus (MRSA)]. Twenty-five patients were discharged home on oral antibiotics. Patients discharged on oral antibiotics had a shorter duration of fever, had a more rapid decline in C-reactive protein and were less likely to have MRSA. The frequency of orthopedic complications did not increase in patients who received early transition to oral antibiotics. For patients with MRSA bacteremia, the rates of complications between those who received ≥7 days versus <7 days of vancomycin did not differ. Vancomycin serum troughs >15 µg/mL were not associated with a decreased duration of fever, bacteremia or hospitalization, need for repeat operation or orthopedic complications but were associated with acute kidney injury. CONCLUSIONS: S. aureus BOAIs are associated with substantial morbidity. Early transition to oral therapy may be a safe option for select patients with S. aureus BOAI, including those due to MRSA. Prolonged courses of vancomycin and vancomycin troughs >15 μg/mL were not associated with improved outcomes for MRSA OAI.
BACKGROUND:Bacteremia is often one factor used in deciding the need for prolonged intravenous antimicrobial therapy in osteoarticular infections (OAIs). We examined treatment practices and outcomes of Staphylococcus aureus bacteremic osteoarticular infections (BOAIs) evaluated at Texas Children's Hospital. METHODS: Cases of acute hematogenous OAI in children with positive blood cultures for S. aureus at Texas Children's Hospital between 2011 and 2014 were reviewed. Orthopedic complications included chronic osteomyelitis, growth arrest, pathologic fracture, avascular necrosis and chronic dislocation. Acute kidney injury was defined as a doubling of the baseline creatinine. RESULTS: One hundred and ninety-two cases of S. aureus OAI were identified with 102 cases of BOAI included [35 methicillin-resistant S. aureus (MRSA)]. Twenty-five patients were discharged home on oral antibiotics. Patients discharged on oral antibiotics had a shorter duration of fever, had a more rapid decline in C-reactive protein and were less likely to have MRSA. The frequency of orthopedic complications did not increase in patients who received early transition to oral antibiotics. For patients with MRSA bacteremia, the rates of complications between those who received ≥7 days versus <7 days of vancomycin did not differ. Vancomycin serum troughs >15 µg/mL were not associated with a decreased duration of fever, bacteremia or hospitalization, need for repeat operation or orthopedic complications but were associated with acute kidney injury. CONCLUSIONS:S. aureus BOAIs are associated with substantial morbidity. Early transition to oral therapy may be a safe option for select patients with S. aureus BOAI, including those due to MRSA. Prolonged courses of vancomycin and vancomycin troughs >15 μg/mL were not associated with improved outcomes for MRSA OAI.
Authors: J Chase McNeil; Andrea R Forbes; Jesus G Vallejo; Anthony R Flores; Kristina G Hultén; Edward O Mason; Sheldon L Kaplan Journal: Pediatrics Date: 2016-04-08 Impact factor: 7.124
Authors: Brady S Moffett; Pamela S Hilvers; Kimberly Dinh; Ayse A Arikan; Paul Checchia; Ronald Bronicki Journal: Congenit Heart Dis Date: 2014-06-17 Impact factor: 2.007
Authors: Natasha E Holmes; John D Turnidge; Wendy J Munckhof; J Owen Robinson; Tony M Korman; Matthew V N O'Sullivan; Tara L Anderson; Sally A Roberts; Sanchia J C Warren; Wei Gao; Benjamin P Howden; Paul D R Johnson Journal: Antimicrob Agents Chemother Date: 2013-01-18 Impact factor: 5.191
Authors: J Chase McNeil; Eric Y Kok; Andrea R Forbes; Linda Lamberth; Kristina G Hulten; Jesus G Vallejo; Edward O Mason; Sheldon L Kaplan Journal: Pediatr Infect Dis J Date: 2016-03 Impact factor: 2.129
Authors: J Chase McNeil; Lauren M Sommer; Mary Boyle; Patrick Hogan; Jesus G Vallejo; Kristina G Hultén; Anthony R Flores; Sheldon L Kaplan; Stephanie Fritz Journal: Antimicrob Agents Chemother Date: 2020-08-20 Impact factor: 5.191
Authors: Eric Y Kok; Jesus G Vallejo; Lauren M Sommer; Louie Rosas; Sheldon L Kaplan; Kristina G Hulten; J Chase McNeil Journal: Antimicrob Agents Chemother Date: 2018-04-26 Impact factor: 5.191
Authors: Sarah Grace Gunter; Mary Joyce B Wingler; David A Cretella; Jamie L Wagner; Katie E Barber; Kayla R Stover Journal: Pharmacy (Basel) Date: 2022-01-15
Authors: Zaid Alhinai; Morvarid Elahi; Sangshin Park; Bill Foo; Brian Lee; Kimberle Chapin; Michael Koster; Pablo J Sánchez; Ian C Michelow Journal: Clin Infect Dis Date: 2020-12-03 Impact factor: 9.079